Rheumathoid Arthritis and Pregnancy
DOI:
https://doi.org/10.5457/ams.v39i1%20Suppl..192Keywords:
rheumatoid arthritis, pregnancy, medicationsAbstract
Rheumatologists often consider the dilemma about treating rheumatoid arthritis during pregnancy. Pregnancy alters the immune state, possibly contributing to a change in the course of RA. Disease activity was found to decrease during pregnancy but to increase after delivery. In about three fourths of pregnancies, the symptoms of the disease lessen. RA does not adversely affect pregnancy outcome. The RA monitoring during pregnancy include: identifying the activity of rheumatoid arthritis (RA), complications related to pregnancy, and adverse effects of the various medications. It is important to counsel patients about the teratogenicity and adverse effects of the medications used to treat rheumatoid arthritis (RA) before starting therapy. Patients may need a reminder about the importance of using contraception during DMARD therapy, especially methotrexate, leflunomide, and cyclophosphamide. Some of these medications may need to be discontinued several months before conception is planned (MTX at least 3 months before conception, leflunomide at least 2 years before conception). Women with RA who want to breastfeed are encouraged to do so. Careful planning, consulting with rheumatologist and gynecologist, adequate timing of the pregnancy and prenatal and postnatal care can result in pregnancy and motherhood which presents joy rather than difficulty for the patients with rheumatoid arthritis.
Downloads
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
